Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review
- PMID: 37736904
- PMCID: PMC10514867
- DOI: 10.3390/pharmacy11050131
Methadone Treatment Gap in Tennessee and How Medication Units Could Bridge the Gap: A Review
Abstract
The opioid epidemic has been an ongoing public health concern in the United States (US) for the last few decades. The number of overdose deaths involving opioids, hereafter referred to as overdose deaths, has increased yearly since the mid-1990s. One treatment modality for opioid use disorder (OUD) is medication-assisted treatment (MAT). As of 2022, only three pharmacotherapy options have been approved by the Food and Drug Administration (FDA) for treating OUD: buprenorphine, methadone, and naltrexone. Unlike buprenorphine and naltrexone, methadone dispensing and administrating are restricted to opioid treatment programs (OTPs). To date, Tennessee has no medication units, and administration and dispensing of methadone is limited to licensed OTPs. This review details the research process used to develop a policy draft for medication units in Tennessee. This review is comprised of three parts: (1) a rapid review aimed at identifying obstacles and facilitators to OTP access in the US, (2) a descriptive analysis of Tennessee's geographic availability of OTPs, pharmacies, and federally qualified health centers (FQHCs), and (3) policy mapping of 21 US states' OTP regulations. In the rapid review, a total of 486 articles were imported into EndNote from PubMed and Embase. After removing 152 duplicates, 357 articles were screened based on their title and abstract. Thus, 34 articles underwent a full-text review to identify articles that addressed the accessibility of methadone treatment for OUD. A total of 18 articles were identified and analyzed. A descriptive analysis of Tennessee's availability of OTP showed that the state has 22 OTPs. All 22 OTPs were matched to a county and a region based on their address resulting in 15 counties (16%) and all three regions having at least one OTP. A total of 260 FQHCs and 2294 pharmacies are in Tennessee. Each facility was matched to a county based on its address resulting in 70 counties (74%) having at least one FQHC and 94 counties (99%) having at least one pharmacy. As of 31 December 2022, 17 states mentioned medication units in their state-level OTP regulations. Utilizing the regulations for the eleven states with medication units and federal guidelines, a policy draft was created for Tennessee's medication units.
Keywords: medication units; methadone; opioid treatment program; opioid use disorder.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Expanding access to methadone treatment in Ohio through federally qualified health centers and a chain pharmacy: A geospatial modeling analysis.Drug Alcohol Depend. 2021 Mar 1;220:108534. doi: 10.1016/j.drugalcdep.2021.108534. Epub 2021 Jan 19. Drug Alcohol Depend. 2021. PMID: 33497963 Free PMC article.
-
Pharmacy-based methadone treatment in the US: views of pharmacists and opioid treatment program staff.Subst Abuse Treat Prev Policy. 2023 Sep 11;18(1):55. doi: 10.1186/s13011-023-00563-w. Subst Abuse Treat Prev Policy. 2023. PMID: 37697326 Free PMC article.
-
Characteristics and current clinical practices of opioid treatment programs in the United States.Drug Alcohol Depend. 2019 Dec 1;205:107616. doi: 10.1016/j.drugalcdep.2019.107616. Epub 2019 Oct 17. Drug Alcohol Depend. 2019. PMID: 31678836
-
Trends in the Use of Methadone and Buprenorphine at Substance Abuse Treatment Facilities: 2003 to 2011.2013 Apr 23. In: The CBHSQ Report. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2013–. 2013 Apr 23. In: The CBHSQ Report. Rockville (MD): Substance Abuse and Mental Health Services Administration (US); 2013–. PMID: 27606405 Free Books & Documents. Review.
-
Review of medication-assisted treatment for opioid use disorder.J Osteopath Med. 2022 Mar 14;122(7):367-374. doi: 10.1515/jom-2021-0163. J Osteopath Med. 2022. PMID: 35285220 Review.
Cited by
-
Potential improvement in spatial accessibility of methadone treatment with integration into other outpatient substance use disorder treatment programs, New York City, 2024.PLoS One. 2025 Feb 5;20(2):e0317967. doi: 10.1371/journal.pone.0317967. eCollection 2025. PLoS One. 2025. PMID: 39908249 Free PMC article.
-
Spatial accessibility of substance use disorder treatment programs, compared with other health care facilities, in New York State, 2024.Addict Sci Clin Pract. 2025 Jul 31;20(1):60. doi: 10.1186/s13722-025-00592-9. Addict Sci Clin Pract. 2025. PMID: 40745341 Free PMC article.
References
-
- Centers for Disease Control and Prevention Understanding the Opioid Overdose Epidemic|Opioids|CDC. [(accessed on 6 October 2022)];2022 Available online: https://www.cdc.gov/opioids/basics/epidemic.html.
-
- Centers for Disease Control and Prevention Data Overview|Opioids|CDC. [(accessed on 6 October 2022)];2022 Available online: https://www.cdc.gov/opioids/data/index.html.
-
- Congressional Budget Office The Opioid Crisis and Federal Policy Responses. [(accessed on 6 October 2022)];2022 Available online: https://www.cbo.gov/publication/58221.
-
- Department of Human and Health Services, Adminstration for Strategic Preparedness and Response Declarations of a Public Health Emergency. [(accessed on 6 October 2022)]; Available online: https://aspr.hhs.gov/legal/PHE/Pages/default.aspx.
-
- American Medical Association AMA Overdose Epidemic Report. 2022. [(accessed on 6 October 2022)]. Available online: https://www.ama-assn.org/system/files/ama-overdose-epidemic-report.pdf.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous